Jafron Biomedical’s Blood Purification Devices Gain EU Market Approval Under MDR
Jafron Biomedical Co., Ltd, a prominent player in the blood purification sector based in China,...
Product approvals
Beijing Balance Medical Secures NMPA Nod for Renatus Transcatheter Aortic Valve System
BEIJING—Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has received market approval from the National...
Sino Medical Sciences Secures Hong Kong Approval for Coronary Balloon Dilation Catheter
HONG KONG—Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in...
Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China
NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a...
Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China
Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...
JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication
JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Legend Biotech’s Carvykti Receives NMPA Approval for Relapsed/Refractory Multiple Myeloma After Multi-Center Phase II Study
Legend Biotech Corporation (NASDAQ: LEGN) has secured a significant milestone with the announcement of marketing...
Jiangsu Hengrui’s Vunakizumab Receives NMPA Approval as First Homegrown Autoimmune IL-17A Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...
Chongqing Genrix Biopharmaceutical Receives NMPA Approval for Xeligekimab, First Domestic Anti-IL-17 Antibody
Chongqing Genrix Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has received marketing approval from China’s...
Regeneron Secures EU Approval for Ordspono, Its First Bispecific Antibody
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has secured its first global market approval for Ordspono (odronextamab)...
Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions
Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai...
Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments
Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...
Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA
Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices...
Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer
Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...
Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China
Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...
Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...
J&J’s Rybrevant-Lazclude Combo Approved by FDA, Challenging AstraZeneca’s Tagrisso in NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) has secured a new market approval in the United...
Johnson & Johnson’s Rybrevant-Lazclude Combo Approved by FDA for First-Line NSCLC Treatment
NEW YORK—Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has secured a significant regulatory milestone...
MicroPort MedTech’s ReeAmber Catheter Wins NMPA Nod for Peripheral Artery Treatments
SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device...
Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment
TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...